Pharma was supposed to be the COVID winner. And it was - for about 18 months. Then came three years of underperformance that wiped out much of the excess returns. The full story of Indian pharma stocks during and after COVID is a useful case study in sector investing, narrative timing, and mean reversion.
The Pre-COVID Starting Point
In early 2020, before the pandemic, Indian pharma stocks were already recovering from a multi-year headwind. US FDA warning letters, pricing pressure in the US generic market, and domestic pricing caps had weighed on earnings from 2015 to 2019. The Nifty Pharma index was trading around 7,500-8,000 at the start of 2020, below its 2015 peak of approximately 11,000.
Valuations were not stretched. Many large cap pharma names were trading at 15-20x earnings, below the broader Nifty 50 valuation.
The March 2020 Crash: Pharma Was Not Spared
A common misconception is that pharma stocks were immune to the March 2020 crash because “healthcare is defensive.” This did not happen. The Nifty Pharma index fell from around 8,000 in January 2020 to approximately 6,200 in March 2020 - a 22-25% drawdown.
The reason: the March 2020 crash was not a healthcare crisis selloff - it was a liquidity and margin call event. Everything sold off simultaneously as investors worldwide raised cash.
The COVID Rally: April 2020 to October 2021
What followed was exceptional. Indian pharma stocks began rallying on multiple tailwinds:
- Raw material exports: India supplies 20-25% of global generic medicine volumes. Demand for antibiotics, antivirals, and related APIs surged.
- API (Active Pharmaceutical Ingredient) independence narrative: Supply chain disruptions created demand for domestic API manufacturing capacity.
- Vaccine plays: Companies like Serum Institute (unlisted), Biological E (unlisted), Zydus (listed) had COVID vaccine involvement.
- Defensive reclassification: After the initial crash, pharma was reclassified by the market as a “defensive” sector, attracting investors seeking safe haven plays.
| Stock | Mar 2020 Low | Oct 2021 High | Gain |
|---|---|---|---|
| Sun Pharma | Rs 325 | Rs 830 | +155% |
| Dr Reddy’s Labs | Rs 2,700 | Rs 5,200 | +93% |
| Cipla | Rs 525 | Rs 1,000 | +90% |
| Divis Laboratories | Rs 1,550 | Rs 5,400 | +248% |
| Biocon | Rs 250 | Rs 470 | +88% |
The Nifty Pharma index went from its March 2020 low of approximately 6,200 to approximately 15,000 by October 2021 - a 140% gain in 18 months.
The Post-COVID Reality: 2022 Onwards
From October 2021, the narrative shifted. US generic drug price erosion resumed. Raw material costs increased due to China supply issues. The India domestic pharma market grew steadily but not explosively. The COVID tailwind disappeared.
The Nifty Pharma index peaked around 15,000-15,500 in late 2021 and spent 2022-2023 declining to around 12,000-13,000. Individual stocks showed worse drawdowns.
| Stock | Oct 2021 Peak | Dec 2022 Low | Drawdown |
|---|---|---|---|
| Divis Laboratories | Rs 5,400 | Rs 2,800 | -48% |
| Biocon | Rs 470 | Rs 200 | -57% |
| Sun Pharma | Rs 830 | Rs 830 (held better) | Near flat |
| Dr Reddy’s Labs | Rs 5,200 | Rs 4,200 | -19% |
| Cipla | Rs 1,000 | Rs 900 (held relatively) | -10% |
Differentiated Performance: Business Model Mattered
Not all pharma stocks behaved the same. The difference came down to US generic drug revenue concentration and API exposure:
- Companies with high US generic revenue (Divis, Biocon, Sun Pharma US generics segment) faced more pressure as US pricing normalised
- Domestic-focused companies (Torrent, Abbott India, Alkem) held up significantly better through 2022-2023
- API manufacturers that had rallied on the “atmanirbhar API” narrative gave back gains as China supply resumed normalcy
The Nifty Pharma Index vs Nifty 50: Full COVID Cycle
If you measure from January 2020 to December 2023 (full cycle including the COVID crash, rally, and correction):
- Nifty Pharma TRI: Approximately 14-16% CAGR
- Nifty 50 TRI: Approximately 15-18% CAGR
By the end of the four-year period, pharma as a sector did not materially outperform the broader market. The dramatic rally and subsequent correction netted out to roughly market-level returns, but with significantly higher volatility.
The Sector Fund Investor Experience
An investor who bought a pharma sector fund at the October 2021 peak (after watching the 140% rally from the COVID bottom) would have experienced:
- 30-40% drawdown by late 2022
- Slow recovery through 2023-2024
- Still potentially below the entry price adjusted for inflation after 2+ years
This is the typical thematic fund investor experience: entering after the rally, experiencing the correction, and waiting for recovery.
What Drives Pharma Valuations Structurally
Indian pharma valuations are driven by four factors:
- US FDA clearances and new drug approvals for US market entry
- Domestic branded generic price growth (DPCO pricing caps matter)
- API manufacturing capacity and API export growth
- Acquisitions of branded products or complex generic pipelines
None of these are COVID-specific drivers. The COVID narrative inflated valuations beyond what the structural business warranted, which is why the correction was significant.
Bottom Line
Indian pharma stocks did not have a simple “COVID winner” story. They crashed 22% in March 2020 with everything else, rallied 140% from the COVID low to October 2021 on genuine near-term tailwinds and sector re-rating, then corrected 30-50% in specific stocks as US generic pricing pressure returned and the COVID narrative expired. Measured over the full cycle from January 2020 to December 2023, pharma returned approximately the same as Nifty 50 but with much higher volatility. Investors who bought at the 2021 peak on the COVID narrative underperformed. Those who held diversified index funds through the same period achieved similar returns without the sector-specific whipsaw.
Comments